EVAS治疗EVAR后III型内漏的国际多中心回顾性研究
这项国际多中心回顾性队列研究纳入8家欧洲中心的20例EVAR后III型内漏患者,评估EVAS补救治疗的技术成功与临床结局。技术成功率95%,1例术后心肌梗死死亡;平均随访22.8个月,1年无临床失败率77.5%,无继发破裂,但部分患者出现瘤体增大和再干预。
要点
- EVAS可安全用于EVAR后III型内漏的补救治疗,技术成功率高且短期无继发破裂。
- 1年无临床失败率77.5%,与再干预和瘤体增大相关,需延长随访。
- 术后可出现新发Ia型或IIIa型内漏,需密切影像学监测。
核心结论
- EVAS补救治疗III型内漏技术成功率可接受,30天死亡率低,短期随访无继发破裂。
- 临床成功率相对较低,与再干预和瘤体增大相关,需延长随访。
研究设计与样本
- 国际多中心回顾性观察性队列研究,纳入8家欧洲机构的数据。
- 共识别20例EVAR后III型内漏接受EVAS治疗的患者,其中80%为IIIb型,20%为IIIa型。
主要发现
- EVAR至EVAS的中位时间49.5个月(28.5-89),EVAS术前平均AAA直径76.6±19.9 mm。
- 技术成功率达95%,1例因术后心肌梗死死亡导致技术失败。
- 平均随访22.8±15.2个月,1例出现Ia型内漏,1例在未治疗位置出现新发IIIa型内漏。
- 5例患者出现瘤体增大,5例接受AAA相关再干预,指征包括瘤体增大伴II型内漏(n=3)、Ia型内漏(n=1)和髂动脉瘤(n=1)。
- 1年随访时,无临床失败率77.5%,无全因死亡率94.7%,无动脉瘤相关死亡率95%,无动脉瘤相关再干预率93.8%。
临床怎么用
- 对于EVAR后III型内漏,尤其是靠近血流分叉处的内漏,EVAS可作为补救治疗选项。
- 术后需密切影像学随访以监测新发内漏和瘤体增大,必要时及时再干预。
局限性
- 回顾性观察性设计,样本量较小(20例),随访时间较短(平均22.8个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Type III endoleaks post-endovascular aortic aneurysm repair (EVAR) warrant treatment because they increase pressure within the aneurysm sac leading to increased rupture risk. The treatment may be difficult with regular endovascular devices. Endovascular aneurysm sealing (EVAS) might provide a treatment option for type III endoleaks, especially if located near the flow divider. This study aims to analyze clinical outcomes of EVAS for type III endoleaks after EVAR. METHODS: This is an international, retrospective, observational cohort study including data from 8 European institutions. RESULTS: A total of 20 patients were identified of which 80% had a type IIIb endoleak and the remainder (20%) a type IIIa endoleak. The median time between EVAR and EVAS was 49.5 months (28.5-89). Mean AAA diameter prior to EVAS revision was 76.6±19.9 mm. Technical success was achieved in 95%, 1 patient had technical failure due to a postoperative myocardial infarction resulting in death. Mean follow-up was 22.8±15.2 months. During follow-up 1 patient had a type Ia endoleak, and 1 patient had a new type IIIa endoleak at an untreated location. There were 5 patients with aneurysm growth. Five patients underwent AAA-related reinterventions indications being: growth with type II endoleak (n=3), type Ia endoleak (n=1), and iliac aneurysm (n=1). At 1-year follow-up, the freedom from clinical failure was 77.5%, freedom from all-cause mortality 94.7%, freedom from aneurysm-related mortality 95%, and freedom from aneurysm-related reinterventions 93.8%. CONCLUSION: The EVAS relining can be safely performed to treat type III endoleaks with an acceptable technical success rate, a low 30-day mortality rate and no secondary ruptures at short-term follow-up. The relatively low clinical success rates, related to reinterventions and AAA enlargement, highlight the need for prolonged follow-up.
引用
- Zoethout AC, Ketting S, Zeebregts CJ, et al. An International, Multicenter Retrospective Observational Study to Assess Technical Success and Clinical Outcomes of Patients Treated with an Endovascular Aneurysm Sealing Device for Type III Endoleak. J Endovasc Ther. 2021. PMID: 34342235. doi:10.1177/15266028211031933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。